HuGEMM™ Human PD-1 Knock-In Model

The HuGEMM PD-1 knock-in mouse provides a translational model for testing your human-specific anti-PD-1 agents. This model has humanized PD-1 receptors and a functional mouse immune system.

The PD-1 model was developed by knocking-in human exon 2 to replace its mouse counterpart. This allows the in vivo efficacy evaluation of human therapeutic antibodies which recognize the humanized receptor.

• Evaluate your human specific biological therapies in vivo when no mouse ortholog is available
  
  
• Efficiently study a range of targets for human immunotherapies
  
  
• Save study resources by using a cost-effective alternative to more complex fully humanized models

Model Characterization Data

×

Figure 1: The chimeric h/mPD-1 protein binds in vitro to both mouse and human PD-L1 as efficiently as the human PD-1 receptor (upper panel). The chimeric protein is also recognized by anti-human PD-1 antibodies (lower panel), which disrupts the PD-1/PD-L1 interaction

Figure 1: The chimeric h/mPD-1 protein binds in vitro to both mouse and human PD-L1 as efficiently as the human PD-1 receptor (upper panel). The chimeric protein is also recognized by anti-human PD-1 antibodies (lower panel), which disrupts the PD-1/PD-L1 interaction

×

Figure 2: Evaluation of Opdivo^® analogue efficacy in HuGEMM PD-1 model. Inhibition of subcutaneous MC38 tumor growth is observed following treatment with the anti-hPD-1 antibody.

Figure 2: Validation of HuGEMM PD-1 with an analog of Opdivo^®. Dose dependent inhibition of subcutaneous MC38 tumor growth is observed following treatment with the anti-hPD-1 antibody.